Tool effective for rapid cataract screening

Article

Catatrac may be a low-cost and effective tool for the rapid screening of visually significant cataracts in the developing world, claims a paper in the journal Eye.

Catatrac may be a low-cost and effective tool for the rapid screening of visually significant cataracts in the developing world, claims a paper in the journal Eye.

A team led by Dr M.Q. Rahman, Tennent Institute of Ophthalmology, Gartnavel General Hospital, Glasgow, UK, divided 122 eyes of 73 patients into two groups- mild cataracts with logMAR acuities of less than 0.48 and advanced cataracts with logMAR acuities greater than or equal to 0.48.

All patients were assessed without pharmacological dilation in a dimly lit room. A slit lamp was used to examine each patient and the LOCS III classification system was used to grade cataracts.

Of the patients studied, 39 had mild cataracts, 43 eyes had advanced cataracts and there were 40 control eyes with no cataracts. The Catatrac device had a specificity of 95%, a sensitivity of 71 to 84.6% and κ values between 0.67 and 0.80 for agreement with slit lamp assessment.

Overall, the Catatrac device has a slightly lower sensitivity for mild cataracts the authors state it may be an efficient and cheap tool for screening visually significant cataracts in the developing world.

To read the abstract visit the website.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.